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Abstract 
Somatic cells have been reprogrammed into pluripotent stem cells by introducing a 
combination of several transcription factors, such as Oct3/4, Sox2, Klf4, and c-Myc. 
Induced pluripotent stem (iPS) cells from a patient’s somatic cells could be a useful 
source for drug discovery and cell transplantation therapies. However, most human iPS 
cells are made by viral vectors, such as retrovirus and lentivirus, which integrate the 
reprogramming factors into the host genomes and may increase the risk of tumor 
formation. Several non-integration methods have been reported to overcome the safety 
concern associated with the generation of iPS cells, such as transient expression of the 
reprogramming factors using adenovirus vectors or plasmids, and direct delivery of 
reprogramming proteins. Although these transient expression methods could avoid 
genomic alteration of iPS cells, they are inefficient. Several studies of gene expression, 
epigenetic modification, and differentiation revealed the insufficient reprogramming of 
iPS cells, thus suggesting the need for improvement of the reprogramming procedure 
not only in quantity but also in quality. This report will summarize the current 
knowledge of iPS generation and discuss future reprogramming methods for medical 
application. 
 Introduction 
Reprogramming has been studied extensively for decades. Nuclear transfer into an 
oocyte gives somatic cells pluripotency to produce cloned animals. For example, Dr. J. 
Gurdon and his colleagues showed that frog somatic cell nuclei can be reprogrammed 
after transferred into enucleated oocytes, and they develop into feeding tadpoles (1). 
Reprogramming in vertebrates was also proven by the creation of cloned animals from 
sheep (2) and mice (3). In addition to oocytes, human(4) and mouse ES(5) cells also can 
reprogram somatic cells into an ES cell-like state after cell fusion. These results 
demonstrated that terminally differentiated cells can revert to a state of pluripotency in 
response to external stimulation. 
The accumulated understanding of the mechanisms underlying pluripotency in 
ES cells led to attempts to revert somatic cells into a pluripotent state using defined 
factors. Twenty-four candidate factors were transduced into mouse embryonic 
fibroblasts by retroviral delivery and this identified four factors that can convert 
fibroblasts into induced pluripotent stem cells (iPSC)(6). iPS cells have been generated 
from mouse (6), rat (7, 8), monkey (9), pig (10), dog (11), rabbit (12) and human (13, 
14). Most of the iPS cells are derived using the OCT3/4, SOX2, Klf4, and c-Myc 
reprogramming factors. The original iPS cell induction system used retroviral vectors, 
which integrate transgenes into the host genome. The insertion of tumorigenic genes, 
like c-Myc, and activation of proto-oncogenes by LTR increase the risk of tumor 
formation (15, 16).  
Mouse iPS cells were generated using a plasmid vector in 2008 and showed 
that iPS cells can be induced by the transient expression of reprogramming factors(17). 
The goals of those experiments were to increase transfection efficiency in primary cells 
and to maintain transgene expression long enough (a few weeks) for iPS cell induction. 
Three essential reprogramming factors (Oct3/4, Sox2, and Klf4) were connected in a 
single plasmid using the 2A sequence, which enables expression of multiple proteins 
from a single RNA transcript. The stoichiometric balance of these core transcription 
factors is thought to be important for iPS cell induction, and therefore all six possible 
orders of the factors in retrovirus system were examined to determine the most effective 
arrangement. The three factors were then placed into a plasmid vector with a 
constitutively active CAG promoter, which yielded high expression (18). This vector 
assures co-expression of the three core factors in all of the transfected cells. In addition, 
another expression vector for c-Myc was constructed. The transfection of the plasmids 
into mouse embryonic fibroblasts was repeated multiple times to achieve the sustained 
expression required for iPS cell generation. iPS cell colonies we obtained after four 
weeks, albeit at a very low frequency. As expected, iPS cell clones in which transgenes 
had been integrated into the host genome were frequently observed. However, no 
transgene integration was detected in approximately one third of the established mouse 
iPS cell clones. The integration-free iPS cell clones have the potential to differentiate 
into various cell types of the three germ layers. Furthermore, they were able to form 
chimeric mice when transplanted into blastocysts, which were competent for germline 
transmission.  
The frequency of iPS cell generation by plasmids, however, was very 
inefficient. The estimated efficiency is less than 0.0002%, which is at least 1000-fold 
lower than that of viral induction. The fact that reprogramming efficiency of human 
fibroblasts with retrovirus is approximately 10-fold lower than that of mouse fibroblasts, 
suggested that the generation of integration-free human iPS cells would be extremely 
inefficient using the same method. Subsequently, several methods for integration-free 
human iPS cell generation have been reported. The approach can be divided into four 
groups based on delivery methods of the reprogramming factors; 1) virus(13, 19, 20), 2) 
DNA(21-24), 3) RNA(25), and 4) protein(26)(Table 1). We calculated induction 
efficiency of each method from the best result reported in the article. Because of the 
difference of their experimental settings, it is hard to compare their efficiency correctly. 
However, as predicted, non-integration methods are extremely inefficient in general. 
Notably, recent reports showed significant improvement of non-integration method. 
Sendai virus is a minus strand RNA virus. Fusaki et al. infected Sendai virus vectors 
encoding reprogramming factor into human fibroblasts and obtained iPS cells(20). 
Because Sendai virus replicate its genome in the cytoplasm of infected cells, this vector 
system can stably express reprogramming factors and achieve high reprogramming 
efficiency. The established iPS cells, on the other hand, tended to carry on virus genome 
even after long time culture. To obtain viral-free cells, additional approach was needed 
such as the elimination of virus containing cells through negative selection against virus 
antigen, HN, or using temperature sensitive mutant. Direct delivery of synthetic mRNA 
also generated iPS cell at high efficiency(25). The mRNA sustained high and relatively 
long expression of encoding reprogramming factors by using modified ribonucleotides. 
However reprogramming via modified RNAs is technically difficult, sensitive to 
reagents, and requires labor-intensive procedures. Therefore, further improvements in 
reprogramming methods are absolutely required for reproducible generation of 
integration-free human iPS cells. A summary of several topics associated with iPS cell 
generation and a discussion of the future in reprogramming methods for medical and 
other applications are herein provided. 
 
Myc family 
c-Myc is a potent inducer of reprogramming(27). Its functions are not fully understood; 
however, one of the functions may be direct activation of pluripotent marker genes. 
Though c-Myc is ubiquitously expressed in several cell types, it has essential function 
for maintenance of the pluripotent state in mouse ES cells. Mouse ES cells can be 
maintained by activation of the STAT3 signal through addition of its upstream cytokine, 
leukemia inhibitory factor (LIF). Dalton and colleagues showed that c-Myc is one of 
STAT3 target genes and that forced expression of c-Myc alone can keep mouse ES cells 
in a pluripotent state (28). Both c-Myc and N-Myc inhibit differentiation of mouse ES 
cells into the primitive endoderm lineage, through suppression of Gata-6 expression, the 
master gene (29). Interestingly, the incorporation of c-Myc in the reprogramming 
cocktail promoted the frequency of germ-line transmission from chimeric mice in 
comparison to iPSCs generated without the Myc transgenes (30). Therefore, c-Myc 
affects the net reprogramming process. Another role of c-Myc is acceleration of the cell 
cycle, although it activates the p53 and p21 pathway. More than 4000 sites in the 
genome are reported as c-Myc binding regions (31). Myc binding may loosen chromatin 
structure and facilitate the access of other reprogramming factors to their target 
sequences. c-Myc enhances iPS cell generation at least in part through these 
mechanisms; on the other hand its tumorigenic properties could have inhibitory effect 
on proper reprogramming and increase the frequency of transformed cells during iPS 
generation. Myc also increases the risk of tumor formation when the transgene remain 
in established iPS cells(15).  
The Myc family consists of three genes; c-Myc, N-Myc, and L-Myc. All 
members form heterodimers with Max protein and bind to target DNA. Their entire 
amino acid sequences are similar; however, L-Myc is shorter in the N-terminal region 
than the other two members. Interestingly, the N-terminal region contributes to 
transformation activity in cultured cells. Consistent with this, activation of L-Myc in 
human tumors are less frequently reported. Therefore L-Myc was the candidate for a 
reprogramming enhancer without increasing the tumorigenic risk. Therefore, attempts 
were made to use L-Myc for iPS cell induction(30).  Using L-Myc for the induction of 
mouse iPS cells increases the number of iPS cell colonies in comparison to cells 
transduced with Oct3/4, Sox2, and Klf4, however, the effect was weaker than for c-Myc. 
L-Myc showed less colony formation than c-Myc which results in a higher ration of iPS 
cell colonies among the total number of colonies. In contrast, L-Myc enhanced iPS 
induction more efficiently than c-Myc in human fibroblasts. c-Myc and N-Myc 
markedly increased the formation of non-iPSC colonies, whereas L-Myc did not. 
Therefore, the proportion of human iPS colonies in of the total colonies is significantly 
higher with L-Myc than with c-Myc or N-Myc. Therefore, different functional moieties 
of the Myc proto-oncogene products are involved in the transformation and promotion 
of directed reprogramming. A microarray analysis has shown the enhancing effect of 
L-Myc on reprogramming to be predominantly accomplished by the suppression of 
fibroblast-specific genes. In addition, L-Myc activates showed weaker activation of 
genes related to tumor formation than did c-Myc. These data demonstrated that L-Myc 
may therefore be more suitable for human iPS cell generation than c-Myc. 
 
p53 
The expression of pluripotent marker genes are often found in immature tumor cells. 
For example, breast cancer cells show elevated level of Oct3/4 and Sox2(32, 33). In 
addition, these cancer stem cells have a differentiation potential to transform into 
several cell types. Both immature tumor cells and iPS cells are derived from somatic 
cells and obtain differentiation potential. These similarities suggest an underlying 
common mechanism of reprogramming toward iPS cells and cancer cells and led to an 
examination of the roles of the tumor suppressor gene, p53, during iPS cell 
generation(34). A relationship between the p53 pathway, c-Myc and Klf4 has also been 
reported. The transduction of p53-null MEF with the four reprogramming factors 
revealed marked enhancement of iPS cell colony formation. They formed tightly packed 
compact colony, similar to ES cells. They also express pluripotent marker genes 
including Nanog and ECAT1. The injection of these reprogrammed cells into 
immuno-deficient mice results in the formation of teratomas containing various cell 
types of the three germ layers, such as neuronal tissue, cartilage, muscle, and gut-like 
epithelium. Their pluripotency was further confirmed by chimeric mouse formation. 
Enhancement of reprogramming was also observed by induction of dominant negative 
form of p53 or its shRNA into wild-type human adult dermal fibroblasts. These data 
demonstrated that the loss of p53 markedly accelerates both mouse and human iPS cell 
generation.  
p53 have many cellular functions, including regulation of apoptosis and 
senescence through p21. c-Myc stimulates p53 and then p21 during iPS cell generation, 
which both inhibit the reprogramming process. The forced expression of MDM2 
increases reprogramming efficiency thorough the inhibition of p53. On the other hand, 
p53 suppression may lead to genomic instability; thus continuous suppression should be 
avoided(35). It is important to carefully examine the genomic mutations and 
tumorigenicity of established iPS cell clones. 
The cell cycle seems to play important roles during generation of iPS cells. 
Some of the reprogramming steps are likely to depend on stochastic events, such as the 
initial cell condition, microenvironment, fluctuation of gene expression and epigenetic 
modification. Therefore, an increase in the cell numbers simply increases the chance of 
iPS cell induction. Hanna et al. examined the relationship between cell number and 
reprogramming efficiency using the secondary induction system (36). They argued that 
reprogramming is a continuous stochastic process where almost all mouse donor cells 
eventually give rise to iPS cells after extended cultivation. Inhibition of the p53 and p21 
pathway as well as the expression of Lin28 increases iPS cell generation predominantly 
by acceleration of the rate of cell division. On the other hand, an overexpression of 
Nanog seemed to enhance reprogramming in a proliferation independent manner.  
 
LIN28 
LIN28 is a negative regulator of the Let7 miRNA family. Lin28 induces the uridylation 
of immature let7 RNA by a non-canonical poly (A) polymerase, TUTase4, which leads 
degradation of the RNA(37). Lin28 gradually decreases during ES cell differentiation, 
and mature let-7 family miRNAs becomes detectable with an inverse correlation. The 
targets of mature let7 include oncogenic genes, such as K-Ras and c-Myc. This is 
consistent with the analysis performed by Hanna et al. which showed that Lin28 
accelerates the efficiency of iPS cell generation in a cell cycle dependent manner. 
However, Lin28 also facilitates the expression of Oct4 at the post-transcriptional level 
by direct binding to its mRNA(38). In addition, let-7 family miRNAs promotes 
differentiation of breast cancer cells and inhibits their proliferation (39). Therefore 
Lin28 may facilitate iPS cell generation, not only in a cell cycle dependent manner, but 
also by promoting Oct4 expression and suppressing the differentiation through the 
inhibition of let-7 family microRNA. Addition of Lin28 enhances the reprogramming 
efficiency from both human and mouse fibroblasts. Further studies are required, 
however, to elucidate the precise mechanisms.  
 
ESRRB 
Estrogen receptor related beta (Esrrb) is an orphan nuclear receptor, which has a 
significant homology with estrogen receptors. ESRRB regulates transcription 
constitutively thorough the estrogen response elements or steroidogenic factor-1 
response elements of target genes. The suppression of ESRRB in ES cells results in 
morphological changes and differentiation, thus suggesting an important role in 
self-renewal (40, 41). Esrrb positively regulates the expression of the key pluripotency 
gene Nanog(42), and the overexpression of Esrrb allows for short-term ESC 
maintenance without the addition of exogenous LIF (Zhang et al., 2008). Esrrb is also 
capable of replacing KLF4 in somatic cell reprogramming from MEFs, but to the lesser 




Sall (Sal-like) 4 belongs to the Spalt (Sal) transcription factor family characterized by 
highly conservative C2H2 zinc-finger motifs. Knockdown of Sall4 in mouse ES cells 
results in the loss of the undifferentiated state and differentiation into 
trophectoderm-like cells, suggesting that Sall4 contributes to self-renewal of ES cells(44, 
45). Importantly, many binding sites of Sall4 overlap with those of Oct3/4, Sox2 and 
Nanog in ES cells, as determined by ChIP on chip analyses(46). These data suggest that 
Sall4 plays a pivotal role in pluripotency. Hence, the effect of Sall4 in iPS 
generation(47). Addition of Sall4 to the reprogramming factors increases the iPS colony 
number from MEFs. However, the ectopic expression of SALL4 showed variable 
effects on iPS generation from HDF. Three out of seven lines of HDF showed more 
than 2-fold increment. On the other hand, no such effects were observed in other four 
lines. A possible cause of the effects of SALL4 on different HDF lines is the expression 
levels of endogenous SALL4. A fibroblast line from a 36-year-old female, which 
showed the strongest effect of the SALL4 transgene, had the lowest expression level of 
the endogenous SALL4. Therefore, the addition of Sall4 could be beneficial when 
trying to achieve iPS cell generation from cells with a low endogenous Sall4 expression.  
 
UTF1  
The expression of UTF1 (undifferentiated embryonic cell transcription factor 1) is 
restricted in ES cells, embryonic carcinoma cells, and primordial germ cells. UTF1 
functions as a chromatin-associated transcriptional repressor with a dynamic behavior 
similar to core histones(48). Knockdown of UTF1 in ES cells and embryonic carcinoma 
cells results in a substantial delay or block to differentiation(49). UTF1 may also be 
important for proliferation. These data indicate a possible role for UTF1 in the 
maintenance of a specific epigenetic profile that is required for differentiation and 
proliferation of ES cells. Zhao et al. screened several candidate factors along with 
conventional factors (OCT3/4, SOX2, KLF4, and C-MYC) for their capacity to improve 
reprogramming step, and found a dramatically increase by UTF1 addition(50). They 
also found an inhibitory effect of p53 for reprogramming. However, none of other 
candidates including NANOG, LIN28, DPPA4, DPPA5, ZIC3, BCL-2, h-RAS, TPT1, 
SALL2, NAC1, DAX1, TERT, ZNF206, FOXD3, and REX1, increased iPS cell colony 
formation dramatically in their culture conditions.  
 
TBX3 
Tbx3 is a transcription factor belonging to T-box family. Tbx3 regulates the expression 
of Nanog and Sox2, and is involved in the transcriptional network for the maintenance 
of pluripotency in mouse ES cells(51). The expression of Tbx3 is induced by the 
activation of the PI3K pathway, whereas inhibited by the MAPK signaling. Short 
hairpin RNA (shRNA) mediated loss-of-function assays indicated requirement of Tbx3 
in ES cells(40). Addition of TBX3 in reprogramming factors seemed to improve quality 
of iPS cells(52). Mouse iPS cells induced by Tbx3 together with Oct3/4, Sox2, and Klf4 
do not show any significant difference in global gene expression profile in comparison 
to iPS cells without Tbx3. However, incorporation of Tbx3 increases the frequency of 
germ-cell contribution and germ-line transmission when injected into early mouse 
embryos. Chromatin immunoprecipitation (ChIP)-sequencing revealed that the direct 
regulatory targets of Tbx3shares a large number of common binding sites with Oct4, 
Sox2, and Nanog(52). Tbx3 may increase the probability of fully reprogrammed cells in 
iPS cell population. 
 
miRNA 
miRNAs are small single-stranded RNAs (around 22 nt) that directly interact with target 
mRNAs through complementary base-pairing and inhibit translation of the target genes. 
miRNA would also modify gene expression at a transcriptional level. miRNAs involved 
in many features of cell properties, such as proliferation, apoptosis, and differentiation, 
by fine-tuning gene expression. miR-291-3p, miR-294 or miR-295 increase 
reprogramming efficiency from MEF(53). The three miRNAs share a conserved seed 
sequence, suggesting they work through common targets. They could be downstream 
targets of c-Myc, because the miRNAs did not enhance reprogramming efficiency in the 
presence of c-Myc transgene, and c-Myc binds the promoter region of the cluster. The 




The low efficiency of iPSC induction from somatic cells raises the possibility that the 
precise balance and/or amount of each transgene expression is important for 
reprogramming. Retrovirally induced, fibroblasts can integrate more than 10 copies of 
transgenes, and it is difficult to control the balance and their inserting position. 
Retroviral vectors preferentially integrate into the promoter regions of active loci, where 
the transgene expression level is affected by the flanking promoter and other elements. 
Dramatic epigenetic changes occur during the reprogramming process. This could 
influence endogenous promoter activities and retroviral expression. Therefore, the level 
and balance of retroviral/lentiviral transgene expression can change even after their 
integration. Papapetrou et al. tried to monitor these expression levels through the 
process using lentivirus vectors encoding different fluorescent protein connected with 
each reprogramming factor(55). They infected these vectors into human fibroblasts at 
various multiplicities of infection (MOI), and thus found the iPSC induction rate to be 
highly sensitive to the OCT3/4 dosage. A 3-fold increase of OCT3/4 improved the 
reprogramming efficiency up to 2-fold, whereas 3-fold reduction severely decreased iPS 
generation. Interestingly, excess addition of OCT3/4 transgene spoiled the enhancement. 
On the other hand, a change of the other three factor dosages inhibited the 
reprogramming process. The overexpression of some reprogramming factors, such as 
Nanog, c-Myc and Klf4, can maintain a pluripotent state in mouse ES cells(56). On the 
other hand, the forced overexpression of Oct3/4 or Sox2 results in the differentiation of 
mouse ES cells(57). A small degree of imbalance can be compensated in the mutual 
regulation networks because these reprogramming factors constitute a transcriptional 
circuit and maintain their expression level. However, an excess amount of imbalance 
would be harmful for iPS cell generation and maintenance. 
 
Culture conditions 
iPS cells have been established in the medium for ES cells. The external signals, 
leukemia inhibitory factor and basic fibroblast growth factor are important factors for 
mouse and human ES cell maintenance, respectively. Wnt signaling also supports the 
self-renewal of ES cells. The Wnt3a signal is mediated by glycogen synthase kinase 
(GSK) 3. The absence of the Wnt signal causes GSK3 to inactivate target genes, 
such as -catenin and c-Myc, by phosphorylation and proteasome-mediated degradation. 
Hence, the inhibition of GSK3 with a chemical drug, CHIR99021, results in activation 
of Wnt signaling(8, 58). The addition of Wnt3a or CHIR99021 enhances the 
reprogramming efficiency both from mouse and human(8, 58). Kenpaullone, an 
inhibitor whose targets are GSK3 as well as CDKs, can  replace Klf4 when MEF are 
transduced with Oct3/4, Sox2, and c-Myc (59). TGF-beta and BMP signals regulate 
MET and could also play an important role in the reprogramming process (described 
below)(54, 60).  
O2 tension is also an important aspect for stem cell maintenance and 
differentiation. For instance, low O2 tension, hypoxia, promotes the survival of neural 
crest cells and hematopoietic stem cells, and prevents differentiation of human ES 
cells(61). Therefore, iPS cell induction performed in hypoxic conditions (5% O2), shows 




Epigenetic modifying drugs can also improve iPS generation. For instance, inhibitors of 
DNA methyltransferase, such as 5’-azacytidine and RG108, increase reprogramming 
efficiency(63). A putative mechanism of active DNA demethylation was recently 
reported in a cell-fusion based reprogramming system(64). No consensus mammalian 
DNA demethylase has been identified. A complex consisting of a cytidine deaminase, 
AID, GADD45, and Mbd4, has been implicated in DNA demethylation(65). These 
factors function as an active demethylation complex by a coupled mechanisms of 
AID-dependent deamination of 5-meC followed by thymine base excision by Mbd4. 
AID is primarily known for its role in B cell class switch recombination and 
hypermutation in mammals. Fibroblasts have methylated DNA at the Oct3/4 promoter 
region. The activation and DNA demethylation of the Oct3/4 promoter occurs within 24 
hours after cell fusion with ES cells. Bhutani et al. found that the suppression of AID by 
shRNA inhibits this promoter activation and DNA demethylation status in fused 
cells(64). AID is also involved in genome-wide erasure of DNA methylation in 
primordial germ cells(66). It is unclear whether AID also plays a role in the iPS cell 
induction process.  
A global survey of DNA methylation in iPS cells and their parental origins 
(mostly fibroblasts) shows that iPS cells have rather higher DNA methylation than do 
their origins(67, 68). The upregulation of DNMT3b and DNMT3l occurs during the 
reprogramming process, and might be responsible for de novo methylation during iPS 
cell generation. The abnormal DNA methylation pattern including hypermethylation and 
hypomethylation can cause abnormal differentiation properties of iPS cells. Other 
epigenetic states, like histone methylation and acetylation, probably participate in iPS 
cell reprogramming. Addition of a histone deacetylase (HDAC) inhibitor, valproic acid 
(VPA), improves reprogramming efficiency in both mouse and human fibroblasts(69, 
70). Other HDAC inhibitors, suberoylanilide hydroxamic acid and trichostatin A, also 
increase iPS cell generation from mouse fibroblasts(70). 
 
Origin 
iPS cells can have some memories of their parental sources. iPS cells from peripheral 
blood can differentiate into the hematopoietic linage at a high efficiency(71). They did 
show a differentiation potential into neuronal cells, but the efficiency was low. However, 
iPS cells from different origins show markedly similar gene expression patterns in the 
undifferentiated state. Their clonal diversity is not beyond that of ES cells. Therefore, 
the memory could be epigenetic status at loci that are not directly related to the 
pluripotent status. Several differentially methylated DNA regions (DMR) have been 
reported(67). Although long-time passaging of iPS cells could largely attenuates these 
differences(72), studies of the relationship between DMR and differentiation potentials 
are needed to precisely evaluate iPS cells from different origins. The cell sources of iPS 
cells also influence the safety of the established iPS cells. The neural differentiation of 
mouse iPS cells derived from various tissues including MEF, tail-tip fibroblasts (TTF), 
hepatocyte, and stomach was performed to examine tumorigenicity(73). Clones that 
originated from TTF showed many residual pluripotent cells after three weeks of in 
vitro differentiation into neural sphere, which resulted in teratoma formation when 
transplanted into an immune-deficient mouse brain. The precise mechanism of this 
phenomenon is yet to be determined, but it may be attributable to incomplete 
reprogramming, epigenetic memory and/or genomic stability. A “safe” iPS cell clone, 
showed therapeutic effects in a mouse model of spinal cord injury (74). The origin of 
iPS cells should also be important in human. It is important to consider clinically 
available sources. Human iPS cells have been generated from keratinocytes(75), 
mesenchymal cells in fat(76), oral mucosa (77), dental pulp cells(78), peripheral 
blood(79), and cord blood, in addition to skin fibroblasts(80). The properties and safety 
of these iPS cell clones should therefore be carefully examined. 
 
Clone difference 
Each human ES clone shows a distinct differentiation potential(81). Some tend toward 
the mesoderm linage after embryoid body formation, but others prefer ectoderm 
differentiation. The characteristics of ES/iPS cells are also changed by culture 
conditions, such as growth medium, feeder cells, oxygen concentration, and passage 
methods(82). The culture time and passage number are particularly important with iPS 
cells, since reprogramming seems to continue even after establishment of iPS cell 
colonies. Chin et al. reported that the continual cultivation of iPS cells yields a gene 
expression profile more similar to human ES cells than that of early passages(83). 
However, extended culture itself raises the risk of genomic instability. Some scientists 
believe that human ES/iPS cells in the naïve state have less diversity than that of those 
in the primed state. However, it is important to note that even mouse ES cells 
demonstrate diversity in their differentiation potential.  
 
Naïve iPS cells 
Pluripotent stem cells including iPS cells and ES cells are categorized into two groups 
by their morphology, gene expression profile, and external signal dependence. 
Conventional mouse-type ES/iPS cells, which form compacted dome-shape colony in 
culture, are called “naïve state” cells. They are largely dependent on external LIF 
signals and show a high proliferation rate. On the other hand, human-type ES/iPS cells, 
which show flat colonies, are predominantly dependent on the bFGF signal, and 
proliferate more slowly, are termed “primed state”. Primed stem cells, called epiblast 
stem cells (EpiSC), can be established from mouse epiblasts with the addition of bFGF 
in culture medium(84, 85). The EpiSCs form flat colonies, and can differentiate into 
various cell types; however they fail to form chimeric mice when injected into 
blastocyst. It could be due to the limited differentiation potential of the primed stem 
cells or just show the difference of their developmental stage. The addition of several 
transgenes such as OCT3/4 and KLF4 into conventional human iPS cells could 
successfully convert their status like mouse ES cells(86). These modified human iPS 
cells share several features with naïve stem cells, including morphology, growth 
properties, an X-chromosome activation state, a gene expression profile, and a signaling 
pathway dependence. However, the culture conditions of naïve human pluripotent cells 
seem not to be optimized, because they easily revert to the primed state. Further study 
should be performed to identify and establish stable handling methods for naïve human 
pluripotent stem cells. 
 
 
Mechanisms underlying the reprogramming process 
The reprogramming process has been gradually revealed by intense studies. Araki et al. 
traced the conversion of MEFs to iPS cells via a live cell imaging system(87). They 
introduced the reprogramming factors and observed MEFs dividing several times in a 
morphologically symmetric manner, maintaining a fibroblastic shape. Thereafter, the 
ancestral cells gradually transformed their morphology into an ES-like shape. The 
transformation occurred within 48 hours after retroviral induction of the four factors in 
most cases. Importantly, their time-lapse analysis uncovered frequent failure in 
reprogramming at late stages of iPS induction. One of descendant becomes an iPS cell 
after an asymmetric division of reprogramming cells. However, the other descendant 
with the same retroviral insertion underwent cell death. The process was largely 
dependent on the c-Myc transgene. They frequently found the transient expression of 
GFP driven by the Nanog promoter. This unstable expression may indicate spontaneous 
activation of the locus, and may reflect stochastic events during reprogramming, which 
can be a stressful time for cells.  
MEFs start to lose their mesenchymal character after the induction of 
transgenes, and then transform their shape into epithelial cells, the phenomenon known 
as the mesenchymal-to-epithelial (MET) transition(54, 60). MET is a biological process 
which often occurs during organ development. The molecular analysis revealed that 
reprogramming factors cooperatively induce MET in MEFs. Oct3/4 and Sox2 suppress 
Snail, a key factor of the epithelial-to-mesenchymal transition (EMT), which is the 
opposite of the MET. TGF-beta signals induce the EMT, at least in part, through the 
activation of Snail and thereby negatively regulate the MET. The c-Myc transgene 
enhances MET through the downregulation of TGF-beta signals by suppression of 
TGF-b1 and TGF-b receptor 2 expression. In addition, Klf4 upregulates genes 
associated with epithelial cells, such as E-cadherin. A temporal gene expression analysis 
revealed that the BMP signals promote the MET through the miR-200 family. The 
inhibition of MET by TGF-beta signaling or by siRNA greatly reduced the 
reprogramming efficiency, suggesting that the MET is an important cellular event 
during reprogramming.  
Chan et al. observed human iPS cell induction by live cell imaging in detail and 
found that there are three types of human iPS cells based on the expression profiles of 
cell surface markers and retroviral silencing(88). The three types differed in the 
methylation status of the promoter region of NANOG and OCT3/4 loci and their 
differentiation potential. The best reprogrammed type was positive for the pluripotency 
markers, SSEA-4 and TRA-1-60, and negative for the fibroblast marker, CD13, and 
showed inactivation of the retroviral promoter. Only this cell type could make teratomas 
containing tissues of all three germ layers. The discrimination of the high pluripotency 
cells from iPS cell induction cultures is necessary because the other two types of 
partially reprogrammed cells were morphologically similar to the correctly 
reprogrammed iPS cells.  
 
Conclusion 
Human iPS cells can be established with a variety of methods. There are several 
difference among 1) the cell source, 2) induction method, 3) reprogramming factors, 4) 
culture conditions including small molecular supplements, 5) type of stem cells (naïve 
or primed). Retro/lentiviral induction is sufficient for in vitro use of iPS cells when the 
remaining reprogramming factors do not significantly interrupt designed assays. 
However, the transgene integration and alteration of the endogenous genomic 
organization could cause a negative safety issue when considering medical applications. 
Genomic integration sites of retro- and lentivirus in iPS cells range from 1 to 40, and 
PCR-based analysis can detect all the integration sites. Hence, it may be possible to 
estimate their risk beforehand. Non-integration methods of iPS cell generation have 
been reported, but their induction efficiencies are quite low and may give rise to 
insufficiently reprogrammed iPS cells. These integration-free methods could be 
improved by using better combinations of reprogramming factors, better parental cell 
sources, and better culture conditions. The establishment of methods of iPS cell 
generation for clinical applications is an ongoing process. More comprehensive 
knowledge of the reprogramming process is therefore crucial for future clinical 
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Table 1: iPS induction methods in human fibroblasts 
   




Reprogramming efficiency  
in human fibroblasts e 
Reference 
Virus Retrovirus + OSKM ++++ 13 
 
Lentivirus + OSNL +++ 14 
 
Adenovirus -a OSKM + 19 
 
Sendai virus -b OSKM ++++ 20 
DNA  Episomal plasmid -a OSKMNLT + 24 
 
Transposon -a, c OSKM ++ 21, 22 
 
Minicircle -a OSNL + 23 
RNA RNA - OSKM +++ 25 
Protein Cell transparent protein - OSKM + 26 
      
a, absence of genomic integration should be experimentally examined. 
 b, absence of virus RNA genome should be experimentally examined. 
 c, Transposon vector is integrated into genome, but it can be removed. 
 d, O, OCT3/4; S, SOX2; K, KLF4; M, C-MYC; N, NANOG; L, LIN28; T, SV40-large T antigen. 
 e, +, <0.001%; ++, <0.01%; +++, <0.1%; ++++, >0.1% 
   
 
    
 
 
